INTRODUCTION
Glioblastoma remains a nearly uniformly fatal malignancy, with a median life expectancy of <18 months. The majority of patients experience tumor progression within 6 to 12 months of initiating standard therapy with radiotherapy and temozolomide. 1 The median life expectancy after tumor progression is approximately 8 months to 9 months, and despite the encouraging radiographic response rates with bevacizumab, this figure has not budged. 2, 3 There is evidence that glioma malignant transformation and proliferation may be related to overexpression of platelet-derived growth factor receptor alpha and beta and Erk/mitogen-activated protein kinase (MAPK) pathway activation. 4 In addition, constitutive signaling through the mammalian target of rapamycin (mTOR) signaling pathway, associated with overexpression of epidermal growth factor receptor (EGFR) or EGFR variant III and phosphatase and tensin homolog (PTEN) mutation, has been implicated in gliomagenesis, regulation of cell growth, protein kinase signaling, ribosome biogenesis, and transcription. 5, 6 The critical nature of these 2 pathways is underscored by their genetic alteration in at least 88% of glioblastomas in The Cancer Genome Atlas repository. Sorafenib is a selective inhibitor of wild-type and mutant Raf kinase, vascular endothelial growth factor receptor 2 (VEGFR-2), Fms-related tyrosine kinase 3 (flt-3), c-KIT, and MAPK, with demonstrated activity in renal cell carcinoma, hematologic malignancies, hepatocellular carcinoma, and melanoma. 7 Sorafenib as a single agent is reported to have minimal activity in patients with recurrent glioblastoma. 8 Temsirolimus disrupts mTOR-dependent signaling, and enhances the effect of radiotherapy in the U87MG orthotopic murine model. 9 A prior North Central Cancer Treatment Group (NCCTG) phase 2 study of single-agent temsirolimus in patients with recurrent glioblastoma demonstrated imaging evidence of activity, as measured by a reduction in tumorassociated T2 hyperintensity on magnetic resonance imaging (MRI) 10 ; however, both that study and a separate North American Brain Tumor Consortium (NABTC) study 11 reported disappointing progression-free survival at 6 months (PFS6) figures of <10%.
We hypothesized that dual-pathway blockade by sorafenib and temsirolimus in the treatment of patients with recurrent glioblastoma might result in favorable effects on survival outcome.
MATERIALS AND METHODS

Patient Eligibility
NCCTG study N0572 was a phase 1/2 open-label study in patients with recurrent glioblastoma. The NCCTG is now part of the Alliance for Clinical Trials in Oncology. The study was approved by the institutional review board of each participating institution and conducted in accordance with institutional and federal guidelines for human investigations. All patients signed institutional review board-approved informed consent forms before enrollment. The phase 2 component, which opened to accrual after completion of the phase 1 component, contained 3 arms. Patients who were naive to prior anti-VEGF therapy and in whom debulking surgery was not planned comprised arm B, whereas patients who had received prior anti-VEGF or anti-VEGFR agents constituted arm D. Arm C consisted of patients who initiated protocol therapy 1 week before planned surgical debulking.
Eligible patients had glioblastoma confirmed on central pathology review before enrollment to the treatment trial; one of us (C.G.) performed the central pathology review. Patients were aged 18 years with 2 prior systemic chemotherapy regimens, had radiographically confirmed tumor progression with an Eastern Cooperative Oncology Group performance status 2, were 12 weeks from the completion of radiotherapy and 4 weeks from prior cytotoxic chemotherapy (6 weeks for nitrosoureas), and had stable or decreasing corticosteroid dose. Patients were required to have adequate bone marrow function (white blood cell count 3000/mm 3 , an absolute neutrophil count 1500/mm 3 , platelet count 100,000/mm 3 , and hemoglobin 10/dL), adequate liver function (aspartate aminotransferase 2.5 and bilirubin <2.0 times the upper limit of normal), adequate renal function (creatinine 2 times the upper limit of normal), fasting cholesterol <350 mg/dL (9.0 mmol/L), and fasting triglycerides <400 mg/dL (4.56 mmol/L). Prior intratumoral therapy was excluded unless there was unequivocal remote tumor progression, as was a history of coagulopathy; use of enzyme-inducing antiepileptic drugs; and any history of significant intratumoral, intracerebral, or subarachnoid hemorrhage. Pregnant women and patients with serious intercurrent medical illnesses and conditions that could alter drug metabolism were excluded. Due to the potential teratogenicity of sorafenib and temsirolimus, all patients of childbearing potential were required to use adequate birth control. All patients were requested to provide a tissue sample for submission to a biospecimen repository, where it was earmarked for the National Cancer Institute Molecular Targeted Combinations study to be analyzed with biospecimens from similar trials of targeted agents in other malignancies. Subject enrollment began in March 2008 and concluded in December 2012.
The study has the following ClinicalTrials.gov identifier: NCT00329719.
Patient Evaluation During Study
Medical history and physical examination were performed at baseline and at the start of each 4-week cycle. Laboratory studies were performed weekly for the first cycle and then every 2 weeks. MRI was obtained at baseline and before every other cycle (every 8 weeks). Determination of tumor response was made using the criteria of Macdonald et al. 12 The study team monitored the trial for evidence of severe adverse effects and feasibility problems. The study was monitored by the Mayo Clinic Cancer Center Data Safety Monitoring Board. In addition, the study chair and study statistician reviewed the current study twice per year in conjunction with production of the semiannual NCCTG Group Meeting reports to identify any problems with accrual, toxicity, and endpoints.
Treatment Plan
Both sorafenib and temsirolimus were supplied by the Cancer Therapy Evaluation Program of the Division of Cancer Treatment and Diagnosis at the National Cancer Institute, under a cooperative research and development agreement with Bayer HealthCare and Pfizer Pharmaceuticals. Patients were administered sorafenib orally twice per day and temsirolimus intravenously once weekly.
Phase 1 Study
The phase 1 component (arm A) used a standard "3 1 3" dose escalation design. The starting dose was sorafenib at
Original Article a dose of 200 mg orally twice daily and temsirolimus at a dose of 25 mg intravenously weekly. Six escalating dose levels were planned beyond the starting dose (range, sorafenib 200 mg-400 mg; and temsirolimus, 25 mg-250 mg). Toxicities were graded according to the National Cancer Institute Common Toxicity Criteria (version 3). Dose-limiting toxicities (DLTs) were defined as any of the following adverse events (AEs) deemed at least possibly related to study agents: grade 4 hematologic toxicity, any grade 3 or 4 nonhematologic toxicity in the face of maximal supportive measures, any intolerable grade 2 nonhematological or grade 3 hematological toxicity requiring a dose reduction during the first 28 days of treatment, or any toxicity resulting in a treatment delay of >1 week during the first 28 days of treatment. The maximum tolerated dose (MTD) was based on the tolerability observed during the first 28 days of treatment. The MTD was that dosage at which fewer than one-third of patients experienced a DLT (ie, the dosage at which 0 or 1 of 6 patients experienced a DLT, with the next higher dose having at least 2 of 3 or 2 of 6 patients encountering a DLT). Intrapatient dose reductions of the agent(s) deemed responsible for toxicity were permitted in both the phase 1 and phase 2 portions of the study.
Phase 2 Study
The approval of the anti-VEGF monoclonal antibody bevacizumab in 2009 altered the landscape of treatment among patients with recurrent glioblastoma; consequently, NCCTG N0572 was amended to add arm D for patients who had received prior anti-VEGF therapy. Arms B (anti-VEGF therapy-naive patients) and D (patients who received prior anti-VEGF/VEGFR therapy) used the phase 1 dose of sorafenib that was administered twice daily. A safety run-in cohort for additional temsirolimus MTD determination was added for arm B due to the results of the phase 1 portion. The decision rules of the safety run-in cohort were based on a 313 design. Among the first 6 patients enrolled, if 1 DLT was observed during the first cycle (28 days), the phase 2 trial would proceed as outlined with dose level 0 (25 mg of temsirolimus) as the phase 2 dose. If 2 DLTs were observed during the first cycle, 6 additional patients were enrolled at dose level 1 (20 mg of temsirolimus) and evaluated. If 1 DLT was observed at dose level 1 (20 mg of temsirolimus) on cycle 1, the phase 2 trial proceeded as outlined with dose level 1 as the phase 2 dose. Arm C comprised patients with planned, clinically indicated surgical biopsy or resection at the time of disease recurrence; they received sorafenib twice daily for 15 doses starting 7 days before surgery and temsirolimus at the phase 1-determined MTD level 7 days before surgery. Frozen tumor tissue allocated to the study consisted of 1 to 2 core needle biopsies or up to 1 g of resected tissue in OCT frozen in liquid nitrogen or snap frozen. These tissues were intended for planned drug distribution/biomarker studies. Once patients recovered adequately from surgery, they were eligible to resume sorafenib and temsirolimus beginning on the first day of cycle 1 provided they still met eligibility criteria.
Statistical Analysis
The primary endpoint for the phase 2 portions (arms B and D) of the current study was the percentage of evaluable patients who were alive and progression free at 6 months (PFS6 successes). The phase 2 portions of this study (arms B and D) were identically designed 2-stage Fleming versions of the Simon optimal design in which accrual is not suspended during the interim analyses. Each study required 41 evaluable patients and had 90% power with a 1-sided 0.10 significance level to test for an increase in the PFS6 success rate from 8% to at least 23% (historical PFS6 rate based on a database study of NCCTG studies 967251, 987254, and N997B). The regimen would be classified as promising with respect to increasing the PFS6 success rate in these patient populations if at least 6 successes were observed among the first 41 accrued patients at the phase 2 MTD for each arm separately. One interim analysis also was included for the analysis of each arm separately. If among the first 19 evaluable patients: 1) 2 to 4 patients were considered PFS6 successes, the study would continue to full accrual; 2) if 5 patients were considered PFS6 successes, the regimen would be considered promising and the results could be reported early; or 3) if 1 patients were considered PFS6 successes, the regimen would be considered ineffective in the respective patient population.
PFS and overall survival times were calculated from the start of study therapy to disease progression or death, respectively. Patients who died without documentation of disease progression were considered to have had tumor progression at the time of death unless there was documented evidence that no disease progression occurred before death. Patients who failed to return for evaluation after the initiation of therapy were censored for disease progression on the last day of therapy. The median PFS and overall survival times were estimated using the Kaplan-Meier method. 13 Data collection and statistical analyses were conducted by the NCCTG (Alliance) Statistics and Data Center. Data quality was ensured by review of data by the Alliance Statistics and Data Center and by the study chairperson following Alliance policies. All analyses were based on the study database frozen on February 7, 2017. Table 1 (arm A). There were 6 men and 6 women. The median age of the patients was 52 years (range, 24-76 years) and the median Eastern Cooperative Oncology Group performance status was 1 (range, 0-2). All patients had glioblastoma. Patients had a median of 1 prior chemotherapy regimens (range, 1-3 regimens); none had previously received the anti-VEGF monoclonal antibody bevacizumab. The median followup was 4.0 months (range, 1.6-38.9 months).
MTD and toxicities
DLT was seen in 0 of 3 patients at dose level 0 (sorafenib at a dose of 200 twice daily and temsirolimus at a dose of 25 mg); however, 2 of 3 patients at dose level 1 (sorafenib at a dose of 400 twice daily and temsirolimus at a dose of 25 mg/week) experienced a DLT, consisting of grade 4 gastrointestinal perforation in 1 patient and grade 3 vomiting, anorexia, and fatigue in another. Three additional patients were accrued at dose level 0; 1 of 3 patients experienced a DLT (fatigue) and a second experienced grade 2 rash. Three subjects on the phase 1 arm were replaced because of insufficient dosing. Grade 3 and higher hematologic and nonhematologic AEs are summarized in Tables 2 to 4 . Thus, sorafenib at a dose of 200 mg twice daily and temsirolimus at a dose of 25 mg weekly was determined to be the MTD.
Phase 2 Component
The phase 2 component enrolled subjects between March 2008 and December 2012. The median follow-up was 4.6 months (6.3 months in patients without and 3.9 months in patients with prior bevacizumab exposure).
Arm B
There were 50 patients enrolled to arm A. One patient entered hospice before beginning study treatment, 3 patients were treated at the phase 1 MTD, and 46 patients were treated at the phase 2 dose. Characteristics of the 49 patients treated on the anti-VEGF therapy-naive arm (arm B) of the phase 2 portion are summarized in Table 1 . The first 2 patients enrolled to this arm experienced 6 grade 3 toxicities during cycle 1. An additional 6 patients were enrolled at dose level 1 (20 mg of temsirolimus) for MTD determination. Only 1 DLT was observed during cycle 1 among these 6 patients (grade 3 thrombocytopenia). Consequently the protocol was amended to decrease the phase 2 dose to 20 mg of temsirolimus. There were 46 eligible patients treated at this phase 2 dose. Approximately 77% of patients experienced grade 3 and 29% experienced grade 4 AEs regardless of attribution (Table  2) ; hematologic AEs (Table 3) were less common than nonhematologic ones (Table 4) , with fatigue (29%), hypophosphatemia (20%), hypercholesterolemia (10%), hypertriglyceridemia (10%), and muscle weakness (10%) the most common. One patient died of multiorgan failure while on study therapy. At the time of the interim analysis, 2 (10.5%) of the first 19 patients (treated at 20 mg of temsirolimus) were alive and progression free at 6 months. This was above the prespecified futility Arm C There were 9 evaluable patients enrolled in arm C and treated at the phase 2 dose. No unique toxicities were noted in this presurgical exposure arm. Two of the 9 patients (22.2%; 95% CI, 2.8%-60%) achieved PFS6. This arm did not have a prespecified criterion of treatment success and was similar to arm B. The median time to disease progression was 4.3 months (95% CI, 2.6-31.9 months) and the median overall survival was 6.7 months (95% CI, 2.6-64 months).
Arm D
There were 46 patients enrolled in arm D. One patient was deemed to be ineligible due to beginning treatment <4 weeks from ending bevacizumab and 45 patients were treated at the phase 2 MTD of temsirolimus of 20 mg on arm D. The frequency and spectrum of AEs (Tables (2-4) ) were very similar to those in patients treated on arm B. The 19 patients for whom details of anti-VEGF therapy were available had all received bevacizumab; no patient was known to receive any other anti-VEGF agent. Similar to arm B, at the time of the interim analysis, 2 of the first 19 patients (10.5%) were alive and progression free at 6 months. This was above the prespecified futility stopping rule of 1 of the first 19 patients. This allowed the study to continue to full accrual. Four of the first 41 patients (9.8%; Clopper-Pearson 95% CI, 2.7%-23.1%) and 4 of all patients on arm D (44 patients, less 1 patient who was excluded due to missing information: 9.1%; Clopper-Pearson 95% CI, 2.5%-21.7%) achieved PFS6; thus, arm D did not meet the prespecified criterion of treatment success. The Kaplan-Meier estimate for PFS6 of all arm D patients was 6.8% (95% CI, 2.3%-20.3%). The median PFS was 1.9 months and the median overall survival 3.9 months (range, 0.43-24.6 months). Of 41 patients evaluable for response, 1 (2%) had regression of nonmeasurable enhancing disease, 20 (49%) had stable disease, and 20 (51%) had progressive disease as their best response.
Hematologic and nonhematologic AEs of grade 3 for arms B, C, and D are summarized in Tables 2 to 4 . Figure 1 summarizes all AEs, including lower grades.
DISCUSSION
Glioma cell transformation and proliferation has been associated with Ras pathway-related signaling. 6 Sorafenib is an inhibitor of wild-type and mutant Raf kinase and inhibits other tyrosine kinases related to tumor progression, including VEGFR-2, flt-3, c-KIT, and MAPK. 7 Sorafenib has clinical activity in colorectal cancer and melanoma, and is approved by the US Food and Drug Administration for the treatment of kidney, hepatocellular, and thyroid carcinoma. . ANC indicates absolute neutrophil count; NOS, not otherwise specified mTOR is a member of the phosphatidylinositide 3 0 -kinase (PI3K)-related family, and is a regulator of cell growth, membrane trafficking, protein degradation, protein kinase signaling, ribosome biogenesis, and transcription. 5 Temsirolimus is a rapamycin analog and allosteric inhibitor of mTOR complex I (MTORC1) in association with FK506 that disrupts mTOR-dependent signaling via reaction with the intracellular FK506-binding protein 12.
14 Inhibition of mTOR suppresses downstream signaling events, including activation of 4E-BP1 and ribosomal subunit p70 s6k , proteins that play key roles in ribosomal biogenesis and cap-dependent translation.
14 Phosphorylation of p70 s6 kinase and 4E-BP1 are surrogate indicators of temsirolimus biologic activity in vivo. 15 PTEN, a tumor suppressor gene commonly mutated in high-grade gliomas, is associated with constitutive action of the PI3K/Akt pathway and resistance to apoptosis in tumors. Low PTEN protein expression is strongly linked with sensitivity to temsirolimus in glioblastoma cell lines. 16, 17 In a prior NCCTG phase 2 study for patients with recurrent glioblastoma, temsirolimus was found to be associated with a reduction of T2 hyperintensity on MRI in a significant percentage of patients, which correlated positively with phosphorylation of p70 s6 kinase in pretreatment tumor tissue. 10 Although there was no survival benefit noted in patients with gliomas, temsirolimus has singleagent activity and is approved by the US Food and Drug Administration for metastatic renal cell carcinoma and has European Union approval for mantle cell lymphoma.
There have been prior reports of single-agent sorafenib or temsirolimus as well as of combination therapies in the treatment of patients with recurrent gliomas. The NABTC studied single-agent sorafenib in a large phase 1 study and reported an MTD of 800 mg twice daily without commenting on antitumor activity. 18 In a single-arm phase 2 study of temozolomide plus sorafenib for 32 patients with recurrent glioblastoma, a PFS6 of 9.4% was observed, and 1 partial response on MRI.
7 Temsirolimus (170-250 mg intravenously weekly) monotherapy was administered to 43 patients with recurrent glioblastoma without significant activity; the PFS6 was 2%, with an median time to progression (MTP) of 9 weeks, but temporary stability was observed in 50% of patients. 19 The NCCTG conducted a study (NCCTG-N997B) of temsirolimus monotherapy at a dose of 250 mg intravenously weekly in 65 patients with recurrent glioblastoma. A PFS6 of 7.8% was observed, with a median overall survival of 4.4 months. In a correlative analysis, p70S6K phosphorylation in pretreatment glioblastoma tissue correlated positively with a reduction in peritumoral T2 hyperintensity on MRI. 10 Combinations also have been evaluated. In a study of bevacizumab plus temsirolimus for patients with glioblastoma who developed disease progression after prior radiation and temozolomide, a median PFS of 8 weeks and a median overall survival of 15 weeks were observed, which were not greater than those reported in prior reports with single-agent bevacizumab. 20 NABTC 05-02 was a phase 1/2 trial similar in design to the current study that was initiated concurrently with the current study for patients with recurrent glioblastoma. 21 Thirteen patients received sorafenib at a dose of 800 mg daily and temsirolimus at a dose of 25 mg once weekly (MTD) on the phase 2 component, which was stopped early based on a futility stopping rule because no patients reached the study endpoint (PFS6), and a median PFS was 8 weeks. The combination of sorafenib and temsirolimus has been studied in other tumor types including melanoma, renal cell carcinoma, and hepatocellular carcinoma. Although 1 phase 1 study reached a sorafenib dose of 600 mg daily with temsirolimus at a dose of 25 mg weekly, 22 to the best of our knowledge all the other studies incorporated sorafenib at a dose of 200 mg twice daily with temsirolimus ranging from 10 mg (in hepatocellular carcinoma) to 25 mg weekly. [23] [24] [25] The largest of these studies noted a rate of 84% for grade 3 toxicity, emphasizing the synergistic toxicity of these 2 agents despite the marked dose reduction compared with singleagent doses. 23 Our current phase 2 study involved what to the best of our knowledge is the largest number of patients with glioblastoma treated in a prospective trial with this combination (116 phase 1/2 patients overall, including 49 anti-VEGF therapy-naive patients in arm B and 45 patients with prior anti-VEGF therapy exposure on arm D in the phase 2 component). In patients who were anti-VEGF therapy-naive, greater activity was observed in the current study compared with the NABTC study (PFS6 of 16% vs 0%). The reasons for these differences are not clear, but may be aberrations related to the relatively small sample sizes in these trials. In addition, evidence of activity was noted by the observation of objective radiographic responses in 9% of anti-VEGF therapy-naive patients in the current study. Nonetheless, although the prespecified endpoint for treatment success was reached in anti-VEGF therapy-naive patients, the median PFS (2.6 months) and median overall survival (6.3 months) were not longer than those observed in prior published studies involving patients with recurrent glioblastoma, thereby limiting enthusiasm for further studies of this combination in patients with recurrent glioblastoma.
To the best of our knowledge, the current study represents one of the first published prospective clinical trials including patients with recurrent glioblastoma who progressed while receiving treatment with bevacizumab. This group of patients, who have a notoriously poor prognosis, has grown rapidly since the approval of bevacizumab for recurrent glioblastoma in 2009. Lesser activity was observed (PFS6 of 9% and an objective response rate of 2%) in this subgroup compared with the VEGF therapynaive patients, and the activity of the combination in this post-anti-VEGF therapy cohort was similar to that previously reported in other studies of patients with prior anti-VEGF therapy who subsequently received a bevacizumab plus nitrosourea-containing regimen (PFS6 of 3%) 26 or who received the triple tyrosine kinase receptor inhibitor nintedanib after bevacizumab (PFS at 3 months of 0%). 27 That PFS6 and time to disease progression were superior in the VEGF therapy-naive arm is unsurprising given the notoriously poor outcomes observed after bevacizumab failure in other studies of recurrent glioblastoma. 26, 28 The reduced dosing required for tolerability of the combination may have adversely influenced treatment efficacy. Specifically, a 2-fold reduction in sorafenib and a 10-fold reduction in temsirolimus were necessary with the combination compared with previously tolerated singleagent doses in this population. Moreover, both temsirolimus and sorafenib have limited distribution across an intact blood brain barrier, and the reduced exposure anticipated in non-contrast-enhancing regions of tumor may have further limited activity. 29, 30 Regrettably, plans to analyze tumor tissue effects of study treatment across several National Cancer Institute-funded studies using this combination never reached fruition, and to date we have been unable to pursue measurement of intratumoral drug concentrations and pharmacodynamic effects on the surgical substudy arm C. Certainly, the moderately high frequency of grade 3 AEs (75% of patients) suggested evidence of drug effect, and that higher administered doses would not be reasonable.
A second potential contributor to this trial's negative results may be related to redundancy and feedback loops in these critical signaling pathways. It has been recognized that effective mTOR-1 inhibition with rapamycin in many glioblastomas leads to loss of negative feedback and subsequent increased Akt activation, driving accelerated tumor growth. 31 Furthermore, glioblastomas inevitably manifest multiple activated receptor tyrosine kinases, and the particular activated kinases vary largely from tumor to tumor. 32 Thus, even adequate drug delivery to block the mTOR and MAPK pathways might prove insufficient to stop disease progression. How to overcome these hurdles and successfully target these pathways critical to glioblastoma survival and growth remain a challenge still to be surmounted. Before moving a new targeted agent into clinical trials, adequate preclinical data should exist that the agent crosses the intact blood-brain barrier. Furthermore, free (unbound) levels of the drug should be sufficient to have a potential pharmacodynamic effect. 33 The use of treat-biopsy and biopsy-treat-biopsy paradigms provides invaluable information regarding drug delivery, pharmacodynamics, and potential mechanisms of resistance. 31, 34 The combination of an optimized clinical trial design and promising new classes of agents such as dual PI3K/mTOR inhibitors that should block feedback activation of Akt offers hope of improved outcomes.
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